There has been a lot of debate of late about whether some of the pain in the so-called momentum names in the last month has something to do with growth money coming into the IPO space...
Talk about whiplash. Yesterday's surge upward was met today with, well, a selloff. So, what gives? What's happening here.
This junior growth name still has much room to run based on market potential and new roll-outs.
Even after a lackluster quarter, future remains bright for FedEx
Transitions, if believed, allow investors to look through short term disruption
The news that Hertz is spinning off its equipment rental business reinforces why it remains the best positioned in the car rental group
Just over one year ago, when Allergan stood at about $115, worries abounded, causing the stock to drop to the low $80s by the middle of 2013, as the overall equity market continued to roar. This underperformance spooked many investors, but that low was a huge opportunity, as the stock has posted a stellar run ever since, now at new highs at over $130. I bring this up now because many are talking about a bubble in biotech, particularly given surges from recent IPOs.
All eyes are on the non-farm payroll numbers this morning, but take a look at some bizarre things happening in the U.S. economy right now
Costco is down this morning on a disappointing report. Check out this hidden camera capturing a debate over Costco's drivers
The company still hasn't recovered since its quarterly report. That is a gift and it is time to come into the stock